Trial Profile
Assess the incidence of mutations in the tyrosine kinase domain of the endothelial growth factor receptor in UK patients with newly diagnosed metastatic or recurrent non-small cell lung cancer and to investigate the quality of life of these patients undergoing first-line therapy with erlotinib.
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2010
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Roche
- 07 Dec 2010 New trial record